Glucose oxidase - Karo Pharma

Drug Profile

Glucose oxidase - Karo Pharma

Alternative Names: Glucose oxidase and glucose -Karo Pharma; T268A cold spray

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tanomed; Umea University
  • Developer Karo Pharma AB
  • Class Antivirals; Glucose oxidases
  • Mechanism of Action Immunomodulators; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Common cold

Most Recent Events

  • 04 Aug 2017 Phase II development is ongoing for Common cold (In infants, In children, In adults) in Sweden (Karo Pharma website, August 2017)
  • 01 Jan 2013 Phase-II clinical trials in Common cold (In adults) in Sweden (Intranasal) (NCT01883440, NCT01883453)
  • 01 Oct 2012 Phase-II clinical trials in Common cold (In infants, In children) in Sweden (Intranasal) (NCT01883427)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top